United Kingdom· GB-APID-31065711000001108
Praxbind 2.5g/50ml solution for infusion vials
A idarucizumab product containing idarucizumab, registered in United Kingdom by Boehringer Ingelheim Ltd. The same ATC class is registered in 13 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Idarucizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC V03AB37 (idarucizumab), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 9 of them publish a price we can compare per daily dose
Idarucizumab · ATC V03AB37
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Idarucizumab
- Manufacturer
- Boehringer Ingelheim Ltd
- Country
- United Kingdom (GB)
- ATC code
- V03AB37
- ATC class
- Idarucizumab
- Defined daily dose
- 5 g, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 2
- gtin5012816096189
- gtin5012816099449
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Idarucizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumPraxbind 2.5 g/50 mlBoehringer Ingelheim International
- CanadaPRAXBINDBOEHRINGER INGELHEIM (CANADA) LTD LTEE
- SwitzerlandPraxbind 2.5 g, Injektions- bzw. InfusionslösungBoehringer Ingelheim (Schweiz) GmbH
- CzechiaPRAXBINDBoehringer Ingelheim International GmbH, Ingelheim am Rhein
- SpainPRAXBIND 2.5 G/50 ML SOLUCION INYECTABLE Y PARA PERFUSIONBoehringer Ingelheim International Gmbh
- FinlandPraxbindBoehringer Ingelheim International GmbH
- FrancePRAXBIND 2,5 g/50 ml, solution injectable/pour perfusionBOEHRINGER INGELHEIM INTERNATIONAL
- IrelandPraxbind 2.5 g/50 mL solution for injection/infusionBoehringer Ingelheim International GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Praxbind
- Liechtenstein · Praxbind
- Norway · Praxbind
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/747b0947-5362-468d-94a7-b1b849b81704 GET /v1/drugs/747b0947-5362-468d-94a7-b1b849b81704?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "31065711000001108",
"desc": "Praxbind 2.5g/50ml solution for infusion vials (Boehringer Ingelheim Ltd)",
"form": "Solution for infusion",
"vpid": "31141811000001100",
"source": "dmd",
"vtm_id": "776299005",
"strength": "50 mg",
"substance": "Idarucizumab",
"ingredient": "Idarucizumab",
"supplier_code": "2065401000001103"
}See everything about idarucizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.